Genito-Urinary Medical Oncologist at IRCCS San Raffaele Hospital - PhD Candidate in Molecular Medicine at Vita-Salute San Raffaele University
Milan, MI
Joined June 2017
- Tweets267
- Following319
- Followers461
- Likes1K
Chiara Mercinelli retweeted
Huge congrats @AndreaNecchi & team on this yet another novel trial.
You are always pushing the envelope in bladder cancer!
@CMercinelli @BrigidaMaiorano @giannatempopatr @UroDocAsh @montypal @PGrivasMDPhD @SpiessPhilippe @IBCG_BladderCA
Promising data presented by @AndreaNecchi at #ESMO26 #GDFather-NEO.
Nivo + Visugromab
• Higher response (pCR and ORR)
• At median F/U 15.7 mo: no recurrence observed after pCR
• No new safety signal
Paper out in @NatureMedicine. Congrats Andrea and co-authors !
@myESMO @OncoAlert
Chiara Mercinelli retweeted
This further #ESMO26 @ESMO_Open simultaneous publication is very important for me. @SanRaffaeleMI @MyUniSR
Outcomes of pts with MIBC who decline RC in perioperative setting:
Take-home message:
1. cCR (Milan criteria) is a reliable biomarker and indicator of outcomes with Systemic Rx and reTURBT
2. Pts who do not get cCR could have a very poor prognosis under bladder-saving approaches > intensification with RC/chemoRT is very much needed
Looking forward to ongoing trials (eg EV209, EV309). Congrats to the entire team, also getting Best Poster! @OncoAlert @myESMO @CMercinelli @Anto_cigliola @BrigidaMaiorano @urotoday Piacentini Nasso Serafin et al.
Outcomes of patients with muscle-invasive bladder cancer who declined radical cystectomy in perioperative therapy trials conducted at San Raffaele Comprehensive Cancer Center - ESMO Open esmoopen.com/article/S2059-7…
Chiara Mercinelli retweeted
With #GDFatherNeo #ESMO26 We brought visugromab+nivo combination neoadjuvantly in pts with MIBC after the initial phase 1 data in refractory setting.
33% CR rates vs 8% Nivo+placebo
All pCR pts still event-free (median FUP 15.7m)
Only 1 relapse event in major responders in N+V arm (pTa relapse)
4/5 pCR skipped RC in N+V arm.
Safety was quite good.
Pre-existing CD8+ infiltration associated with N+V Response.
It was an illuminating academic-industry collaboration for me.
Results simultaneously released today in @NatureMedicine
@myESMO @CMercinelli @Anto_cigliola @BrigidaMaiorano @giannatempopatr @DrIacovelli @ciccarese_c and Many more @SanRaffaeleMI @MyUniSR
nature.com/articles/s41591-0…
Chiara Mercinelli retweeted
Fantastic presentation by expert @AndreaNecchi ENERGIZE trial that did not meet its primary endpoint. Interesting ctDNA data;awaiting VOLGA trial at @myESMO #ESMOAmbassadors @OncoAlert @Uromigos @nataliagandur @DrKarineTawagi @shilpaonc @UroDocAsh @CMercinelli @BrigidaMaiorano
🎯 #ESMO26 ENERGIZE ph3 trial presenting by @AndreaNecchi other periop of IO therapy in MIBC! Cis-Gem + Nivo vs Cis-Gem! Other negative study of IO + cisplatin-based chemo!🧐 Reinforce the value of ADC + Pembro in this setting! @OncoAlert @myESMO @GuardConsortium @PGrivasMDPhD @apolo_andrea
Chiara Mercinelli retweeted
Defining clinical complete response after neoadjuvant therapy in #MIBC. @TomFlaigMD @CUAnschutz and @CMercinelli @SanRaffaeleMI join @pjhensley11 @UKYMedicine at #IBCG2026; Dr. Flaig calls #IMvigor011 a turning point for ctDNA. #WatchNow on UroToday > bit.ly/3W6G4RI #IBCG26 @IBCG_BladderCA @UroDocAsh
Chiara Mercinelli retweeted
WATCH: Chiara Mercinelli, MD, (@CMercinelli) discusses a meta-analysis comparing neoadjuvant treatment strategies for cisplatin-eligible muscle-invasive bladder cancer. urologytimes.com/view/networ…
Chiara Mercinelli retweeted
To mark Penile Cancer Awareness Day, the GSRGT is proud to officially launch PCARE — our new patient advocacy initiative supporting people affected by #PenileCancer.
If you are a patient or caregiver looking for support or guidance, please contact us at [email protected] 📩
Special thanks to @SpiessPhilippe, @LuisMedinaMD, and @JadChahoud for bringing this initiative to life.
@drgaganprakash @npaesa @CMercinelli @CurtisPettaway1 @AmerUrological @UroOnc @SUO_YUO @CAU_URO @AndreaNecchi @herneygarcia @PGrivasMDPhD @UroDocAsh @spsutkaMD @montypal @shilpaonc @orchidcancer @karima_oualla @VedangMurthy @UrogerliMD
Chiara Mercinelli retweeted
🧬 Could PSMA PET/CT become more than a staging tool—and actually help us measure treatment response?
Article 📰
sciencedirect.com/science/ar…
PSMA PET/CT Kinetics During Systemic Therapy and Radiotherapy in Hormone-sensitive Prostate Cancer: A Systematic Review
A systematic review of 11 studies evaluated PSMA PET/CT for treatment response assessment in hormone-sensitive #ProstateCancer .
➡️ ADT generally reduced PSMA expression, although an early flare was observed in a subset of lesions, particularly bone metastases.
➡️ Following radiotherapy ☢️ , PSMA reductions appeared greater when ADT was added.
✅ These findings suggest PSMA PET parameters could potentially help personalize treatment monitoring, but their association with long-term oncological outcomes remains to be established.
@JennKa12, @MBauckneht, @ClaudiaKesch, @GGandaglia, @dr_rajwa, @Fabio_Zattoni, @AlbertoMartini_, @veerukasi, @Lara__Rodriguez, @fazekasMD, @TheGiesen, @m_martinamaggi, @CMercinelli, @miszczyk_marcin, @JGomezRivas, @ruimmbernardino, @alibourgi1_ali, @Tilki_De, @GMarra_MD, @EAU_YAUProstate
@OncoAlert 🚨 #LPCCC27
@Silke_Gillessen
@AOmlin
@ProfKHerrmann
@weoncologists
Chiara Mercinelli retweeted
Best part of the meeting is reaching out with friends and colleagues @IBCG_BladderCA @UroDocAsh @shilpaonc @giannatempopatr @PGrivasMDPhD @AndreaNecchi @apolo_andrea @CMercinelli @BrigidaMaiorano @AparnaKamatMD @NehaVapiwala
Chiara Mercinelli retweeted
Wonderful dinner with amazing people at the 20th anniversary of
@IBCG_BladderCA @UroDocAsh @PGrivasMDPhD @giannatempopatr @CMercinelli @spsutkaMD @carme_mir1 @BrigidaMaiorano
Chiara Mercinelli retweeted
Already impressed with the truly global nature of #IBCG26 - and the meeting has not even officially started yet! Hats off to @UroDocAsh for bringing #bladdercancer experts around the 🌍 to discuss key topics from #NMIBC to #mUC. Was pleased to see @karima_oualla 🇲🇦, @giannatempopatr @CMercinelli @BrigidaMaiorano 🇮🇹, @drgaganprakash 🇮🇳 & so many others - anticipating great discussions today!
Chiara Mercinelli retweeted
Incredible to see the growth of @IBCG_BladderCA over 20y. At #IBCG26, @UroDocAsh highlights new members (incl @WesleyYipMD @AbhiTrip87 from @cityofhope), 🌎 site (28 countries!), publications (incl @EUplatinum highest rated article from @shilpaonc @UrogerliMD et al) & society collabs (@GTumorBoard @JSUO_official @TataMemorial @SIU_urology & more). Just brilliant!
Chiara Mercinelli retweeted
Defining the Optimal Therapeutic Approach in Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Novel Strategies Versus Gemcitabine-Cisplatin | @JCOOA_ASCO @ASCO @CMercinelli @Anto_cigliola @BrigidaMaiorano @vale_tateo @SanRaffaeleMI @MyUniSR @OncoAlert @urotoday ascopubs.org/doi/10.1200/OA-…
Chiara Mercinelli retweeted
🚨 Is gemcitabine-cisplatin still the benchmark in MIBC?
Article 📰 ascopubs.org/doi/10.1200/OA-…
Defining the Optimal Therapeutic Approach in Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Novel Strategies Versus Gemcitabine-Cisplatin
A meta-analysis of three phase III trials in cisplatin 🧪eligible muscle-invasive #BladderCancer shows that intensified or immune-based neoadjuvant regimens outperform gemcitabine-cisplatin. ✅EVP produced the strongest improvements in event-free survival, overall survival, and pathologic complete response, while GC plus durvalumab and ddMVAC also improved outcomes. ➡️However, cross-trial differences and limited follow-up warrant caution. The findings underscore a rapidly evolving perioperative landscape and raise important questions about biomarkers 🎯 , overtreatment, toxicity, and bladder preservation.
@CMercinelli
@Anto_cigliola
@BrigidaMaiorano
@UroMoschini
@F_Montorsi
@Albert0Briganti
@AndreaNecchi
Chiara Mercinelli retweeted
Thank you to our growing global community for supporting the GSRGT and our mission!
Interested in rare GU tumors? Follow @gtumors and join our growing global community! 🌎
@SpiessPhilippe @drgaganprakash @npaesa @CMercinelli @AmerUrological @UroOnc @SUO_YUO @CAU_URO @JadChahoud @benristau @PGrivasMDPhD @spsutkaMD @CMercinelli @LuisMedinaMD @herneygarcia @AndreaNecchi @apolo_andrea @VedangMurthy @ARRODRIGUEZMD @montypal @UrogerliMD @dramandeeparora @CurtisPettaway1 @karima_oualla
Chiara Mercinelli retweeted
10 Must-Read Posts in GU Oncology This Week | First Week of August
This week’s selection covers:
• PSMAddition and ¹⁷⁷Lu-PSMA-617 in PSMA+ mHSPC
• MR-guided adaptive SBRT to the prostate bed
• Early enfortumab vedotin rash as a potential response marker
• PSA nadir as a prognostic marker in mHSPC
• Conditional survival in metastatic RCC after first-line nivo/ipi
• Unmet needs in penile cancer
• Neoadjuvant immunotherapy in MIBC: PURE-01, NureCombo, SURE2
• Nicheverse and spatial transcriptomics in ccRCC
• Enzalutamide vs darolutamide doublet therapy in mHSPC
• EORTC 2238 DE-ESCALATE in mHSPC
@katy_beckermann @shilpaonc @fcounago @g_procopio_ @LuisMedinaMD @CMercinelli @nealshore @BertrandTOMBAL @ChrisWeeMD
@AmandaNizamMD @jamecancerdoc @MosheOrnsteinMD
👉 oncodaily.com/genitourinary-…
#GUOncology #OncoDaily
Chiara Mercinelli retweeted
Tumor mutational burden predicts the outcome of patients with muscle-invasive bladder cancer undergoing immune-checkpoint inhibitor-based neoadjuvant therapy - a combined analysis of #PURE01 #SURE02 #NureCombo @CMercinelli @Anto_cigliola @BrigidaMaiorano et al. @SanRaffaeleMI @MyUniSR #TMB @FoundationATCG clinical-genitourinary-cance…
Chiara Mercinelli retweeted
🚨 🚨🚨New Editorial in @EurUrolOncol !
#PROTEUS trial: a landmark study, but are we ready for treatment intensification in high-risk PCa?
We discuss the evidence, unanswered questions, biomarkers, and the evolving role of multimodal care.
sciencedirect.com/science/ar…
